

CITATION REPORT

List of articles citing

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study

DOI: 10.1038/s41416-018-0340-2

British Journal of Cancer, 2019, 120, 172-182.

Source: <https://exaly.com/paper-pdf/74531617/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
40	Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. <i>Targeted Oncology</i> , 2019 , 14, 647-656	5	6
39	Efficacy and Safety of Anti-cancer Biosimilars Compared to Reference Biologics in Oncology: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>BioDrugs</i> , 2019 , 33, 357-371	7.9	6
38	Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 83-92	3.5	3
37	Current situation and challenges regarding biosimilars in Japan: an example of trastuzumab biosimilars for breast cancer. <i>Future Oncology</i> , 2019 , 15, 1353-1361	3.6	6
36	What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?. <i>Breast Care</i> , 2019 , 14, 10-16	2.4	9
35	Biosimilar Trastuzumab in Clinical Trials: Differences or Not?. <i>Breast Care</i> , 2019 , 14, 17-22	2.4	5
34	Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919887044	5.4	13
33	Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. <i>Applied Health Economics and Health Policy</i> , 2020 , 18, 5-16	3.4	18
32	Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. <i>Journal of Cellular Physiology</i> , 2020 , 235, 3142-3156	7	25
31	Towards personalized treatment for early stage HER2-positive breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 233-250	19.4	71
30	Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials. <i>Cancer Chemotherapy and Pharmacology</i> , 2020 , 86, 577-588	3.5	0
29	Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars. <i>Drugs</i> , 2020 , 80, 1811-1830	12.1	8
28	A randomized, double-blind, parallel pharmacokinetic study comparing the trastuzumab biosimilar candidate, AryoTrust [®] , and reference trastuzumab in healthy subjects. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1443-1450	5.9	3
27	Integrative Review of Managed Entry Agreements: Chances and Limitations. <i>Pharmacoeconomics</i> , 2020 , 38, 1165-1185	4.4	12
26	Trastuzumab Biosimilars in the Therapy of Breast Cancer - "Real World" Experiences from Four Bavarian University Breast Centres. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020 , 80, 924-931	2	0
25	2. Therapie des metastasierten Mammakarzinoms. 2020 , 71-120		
24	Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1070-1080	2.2	9

23	How can biosimilars change the trajectory of breast cancer therapy?. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 325-328	3.5	6
22	A Clinical Review of Biosimilars Approved in Oncology. <i>Annals of Pharmacotherapy</i> , 2021 , 55, 362-377	2.9	1
21	Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. <i>BioDrugs</i> , 2021 , 35, 337-350	7.9	3
20	Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center. <i>Pharmaceutics</i> , 2021 , 13,	6.4	
19	Progress in oncology biosimilars till 2020: Scrutinizing comparative studies of biosimilar monoclonal antibodies. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 27, 1195-1204	1.7	1
18	Current state and comparison of the clinical development of bevacizumab, rituximab and trastuzumab biosimilars. <i>Future Oncology</i> , 2021 , 17, 2529-2544	3.6	3
17	Evidence-based public policy making for medicines across countries: findings and implications for the future. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 1019-1052	2.1	7
16	Feasibility of HER2-Targeted Therapy in Advanced Biliary Tract Cancer: A Prospective Pilot Study of Trastuzumab Biosimilar in Combination with Gemcitabine Plus Cisplatin. <i>Cancers</i> , 2021 , 13,	6.6	7
15	Use of Biosimilar Medications in Oncology.. <i>JCO Oncology Practice</i> , 2022 , OP2100771	2.3	1
14	Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera), a trastuzumab biosimilar, under extended in-use conditions.. <i>Journal of Oncology Pharmacy Practice</i> , 2022 , 10781552221074649	1.7	
13	Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.. <i>JAMA Oncology</i> , 2022 ,	13.4	0
12	Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.. <i>BioDrugs</i> , 2022 , 36, 55-69	7.9	0
11	An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review.. <i>Ophthalmology and Therapy</i> , 2022 ,	5	1
10	Biosimilar Monoclonal Antibodies in Latin America.		
9	Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2Positive Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> ,	2.2	0
8	A Review of Trastuzumab Biosimilars in Early Breast Cancer and Real World Outcomes of Neoadjuvant MYL-14010 versus Reference Trastuzumab. <i>Current Oncology</i> , 2022 , 29, 4224-4234	2.8	
7	Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis. <i>Immunopharmacology and Immunotoxicology</i> , 1-7	3.2	0
6	Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. <i>Lancet Oncology, The</i> , 2022 , 23, e348-e358	21.7	0

- 5 Switching Among Biosimilars: A Review of Clinical Evidence. 13, 1
- 4 Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China. 0
- 3 Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer: An Analysis of a Large University Breast Cancer Centre. 0
- 2 Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis. 2023, 37, 205-218 0
- 1 Cardiotoxicity of HER-2-targeted drugs when combined with other drugs: A systematic review and single-rate meta-analysis. 0